Mast cell stabilizers for treatment of chronic inflammatory conditions
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11478463-B2
Publication Date
2022-10-25
Expiration Date
Abstract
The present invention relates to methods for treating chronic inflammatory conditions using a mast cell stabilizing compound. The invention further relates to compositions and dosage forms comprising mast cell stabilizing agents.
Core Innovation
The invention relates to a method of treating or ameliorating chronic inflammation in a subject by administering a therapeutically effective amount of norketotifen or a pharmaceutically acceptable salt thereof. The method is described as treating or ameliorating chronic inflammation through mast cell stabilizer-based therapy, with emphasis on downregulation of mast cell activation. The approach is positioned as preserving adaptive immune function while addressing chronic inflammatory conditions.
The background context addresses limitations of corticosteroids and mediator-blocking approaches for chronic inflammatory conditions. The invention relates to chronic inflammation caused by a pathogen or chronic inflammation caused by a viral infection, as described. Immune mediators referenced include histamine, TNF-α, prostaglandins, leukotrienes, and cytokines, and the therapy is described in relation to mast cell degranulation and mast cell activation syndrome (MCAS).
The described therapeutic concept includes administering a mast cell stabilizing compound for treating or preventing chronic inflammation via a therapeutically or prevention-effective amount. Pharmaceutical compositions and dosage forms are described as comprising norketotifen, optionally with additional anti-inflammatory agents, and are described with broad routes and sustained or extended-release and time-release delivery concepts. Norketotifen is stated to be a preferred compound relative to ketotifen, with reduced drowsiness, ability to use higher doses, and longer half-life.
Claims Coverage
The partial content includes two independent claims, each covering a method of treating or ameliorating chronic inflammation using norketotifen (or a pharmaceutically acceptable salt) with a defined underlying cause (pathogen or viral infection). Across the independent claims, the dependence adds one or more inventive refinements involving addition of an anti-inflammatory agent and whether it is administered in the same composition or separate compositions.
Norketotifen administration for chronic inflammation due to a pathogen
A method of treating or ameliorating chronic inflammation in a subject comprising administering a therapeutically effective amount of norketotifen or a pharmaceutically acceptable salt thereof, wherein the chronic inflammation is due to a pathogen.
Norketotifen administration for chronic inflammation due to a viral infection
A method of treating or ameliorating chronic inflammation in a subject comprising administering a therapeutically effective amount of norketotifen or a pharmaceutically acceptable salt thereof, wherein the chronic inflammation is due to a viral infection.
Overall, the claims coverage centers on administering therapeutically effective norketotifen (or a pharmaceutically acceptable salt) for chronic inflammation, where the inflammation is specified as due to either a pathogen or a viral infection. The dependent claim coverage further supports co-therapy with an additional anti-inflammatory agent and distinguishes administration in the same composition versus separate compositions.
Stated Advantages
Reduced drowsiness relative to ketotifen.
Ability to use higher doses.
Longer half-life versus ketotifen.
Preserves adaptive immune function while treating chronic inflammation.
Treats or ameliorates chronic inflammation by downregulating mast cell activation.
Documented Applications
Treating or ameliorating chronic inflammation in a subject where the chronic inflammation is due to a pathogen.
Treating or ameliorating chronic inflammation in a subject where the chronic inflammation is due to a viral infection.
Treating chronic inflammation by administering a mast cell stabilizing compound, including pharmaceutical compositions comprising norketotifen (optionally with additional anti-inflammatory agents).
Preventing chronic inflammation by administering a prevention-effective amount of a mast cell stabilizing compound.
Interested in licensing this patent?